Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahrukh

Showing results (531-540 of 560) with videos related to

Pageof 56
Sort By:
BMJ Open|April 30, 2021
Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE)Mahrukh Imran, Linda Kwakkenbos, Stephen J McCall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
United European Gastroenterology Journal|December 24, 2025
Increased Disease Burden in Irritable Bowel Syndrome With Comorbid Conditions and Psychiatric Diagnoses in a Multinational European Cohort: Results From the DISCOvERIE ProjectIrina Midenfjord, Mahrukh Khadija, Elias Sundelin, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Annals of Surgical Oncology|September 12, 2020
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and AustraliaMichael J Carr, James Sun, Hidde M Kroon, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancerJohn Michael Bryant, Maria Sandoval, Ryan Putney, et al.
Pageof 56

Showing results (531-540 of 560) with videos related to

Sort By:
Pageof 56
BMJ Open|April 30, 2021
Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE)Mahrukh Imran, Linda Kwakkenbos, Stephen J McCall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
United European Gastroenterology Journal|December 24, 2025
Increased Disease Burden in Irritable Bowel Syndrome With Comorbid Conditions and Psychiatric Diagnoses in a Multinational European Cohort: Results From the DISCOvERIE ProjectIrina Midenfjord, Mahrukh Khadija, Elias Sundelin, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Annals of Surgical Oncology|September 12, 2020
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and AustraliaMichael J Carr, James Sun, Hidde M Kroon, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancerJohn Michael Bryant, Maria Sandoval, Ryan Putney, et al.
Pageof 56